Active drug (BIIB014) at 10, 30, 100, or 300 mg once daily. ( DrugBank: - )
1 disease
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
6 | Parkinson disease | 1 |
6. Parkinson disease
Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00451815 (ClinicalTrials.gov) | January 2003 | 31/1/2006 | BIIB014 Phase 2a Monotherapy | A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Multiple Oral Dose Administration of BIIB014 in Subjects With Early Parkinson’s Disease | Parkinson's Disease | Drug: active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.;Drug: placebo | Biogen Idec | NULL | Withdrawn | 30 Years | 78 Years | Both | Phase 2 | NULL |